Moderna (NASDAQ:MRNA) PT Raised to $106.00

Moderna (NASDAQ:MRNA) had its target price hoisted by Canaccord Genuity Group from $91.00 to $106.00 in a research report released on Friday morning, Benzinga reports. They currently have a hold rating on the stock.

Other research analysts have also issued reports about the stock. Jefferies Financial Group reiterated a buy rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. HSBC reiterated a reduce rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer lifted their price objective on shares of Moderna from $142.00 to $163.00 and gave the company an outperform rating in a research note on Friday. William Blair reiterated a market perform rating on shares of Moderna in a research note on Monday, April 1st. Finally, Royal Bank of Canada boosted their price target on shares of Moderna from $125.00 to $135.00 and gave the company an outperform rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $129.55.

Moderna Price Performance

MRNA opened at $122.13 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a market capitalization of $46.81 billion, a price-to-earnings ratio of -7.79 and a beta of 1.57. The firm’s fifty day moving average price is $105.61 and its two-hundred day moving average price is $94.76. Moderna has a 1 year low of $62.55 and a 1 year high of $142.79.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 EPS. As a group, analysts anticipate that Moderna will post -7.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares in the company, valued at $809,235.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Moderna news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 670 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 139,954 shares of company stock worth $14,822,576. Corporate insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Empowered Funds LLC raised its position in Moderna by 26.8% during the 1st quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock valued at $456,000 after purchasing an additional 904 shares during the last quarter. Empirical Finance LLC raised its holdings in Moderna by 4.7% in the first quarter. Empirical Finance LLC now owns 8,975 shares of the company’s stock worth $956,000 after purchasing an additional 399 shares in the last quarter. Mawer Investment Management Ltd. raised its holdings in Moderna by 6.7% in the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after purchasing an additional 120,621 shares in the last quarter. Advisory Alpha LLC purchased a new stake in shares of Moderna in the first quarter worth $394,000. Finally, John G Ullman & Associates Inc. grew its stake in shares of Moderna by 212.3% in the first quarter. John G Ullman & Associates Inc. now owns 11,400 shares of the company’s stock worth $1,215,000 after acquiring an additional 7,750 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.